He developed extracorporeal membrane oxygenation, or ECMO, a treatment that can sustain patients whose hearts and lungs are ...
EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Positive Phase 3 Results for EB05 in ARDS On October 28, 2025, Edesa ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...
The "Australia Acute Respiratory Distress Syndrome Market Analysis 2025" report has been added to ResearchAndMarkets.com's offering. The Australia Acute Respiratory Distress Syndrome (ARDS) Market is ...
InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients experiencing acute respiratory distress. The European Commission granted ...
Background: Severe COVID-19 infection has been associated with acute respiratory distress syndrome (ARDS) and right ventricular (RV) dysfunction. In this study, we report associations between ...
The following is a summary of “Identification of novel sub-phenotypes of severe ARDS requiring ECMO using latent class analysis,” published in the October 2024 issue of Critical Care by Nishikimi et ...
Acute Respiratory Distress Syndrome (ARDS) is initiated by a primary insult that triggers a cascade of pathological events, including damage to lung epithelial and endothelial cells, extracellular ...
Under 3% of patients studied with severe ARDS used extracorporeal membrane oxygenation. Extracorporeal membrane oxygenation (ECMO) can significantly improve mortality in severe acute respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback